CAS Number104632-26-0
SynonymsN~6~-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride; n'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine; (Pramipexole ); (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; (S)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine; (S)-N6-Propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine; [(6S)-2-Amino(4,5,6,7-tetrahydrobenzothiazol-6-yl)]propylamine; (S)-Pramipexole; U 98528E; MFCD00869076; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; Pramipexole; (S)-2-AMINO-6-(PROPYLAMINO)-4,5,6,7-TETRAHYDROBENZOTHIAZOL TETRAHYDROBENZOTHIAZOL; T56 BN DSJ CZ GM3 &&S Form; (s)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole; Pramipexole(S)-2-Amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole; (S)-N6-Propyl-4,5,6,7-tetrahydrobenzothiazole-2
Molecular FormulaC10H17N3S1
Molecular Weight211.33
Purity98%
Density1.2±0.1 g/cm3
Boiling Point378.0±42.0 °C at 760 mmHg
Melting Point288-290°C
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 104632-26-0 |
| Catalog No. | 2A-9012094 |
| Chinese Name | 普拉克索 |
| Synonyms | N~6~-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride; n'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine; (Pramipexole ); (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; (S)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine; (S)-N6-Propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine; [(6S)-2-Amino(4,5,6,7-tetrahydrobenzothiazol-6-yl)]propylamine; (S)-Pramipexole; U 98528E; MFCD00869076; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; Pramipexole; (S)-2-AMINO-6-(PROPYLAMINO)-4,5,6,7-TETRAHYDROBENZOTHIAZOL TETRAHYDROBENZOTHIAZOL; T56 BN DSJ CZ GM3 &&S Form; (s)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole; Pramipexole(S)-2-Amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole; (S)-N6-Propyl-4,5,6,7-tetrahydrobenzothiazole-2 |
| Molecular Formula | C10H17N3S1 |
| Molecular Weight | 211.33 |
| Purity | 98 |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 378.0±42.0 °C at 760 mmHg |
| Melting Point | 288-290°C |
| Storage Condition | -20°C Freezer |
| Application | Pramipexole is a dopamine receptor agonist, effective in Parkinson's disease and hyperactivity leg syndrome. |
| HTC | 2934999090 |
| MDL Number | MFCD00869076 |
| SMILES | CCCNC1CCc2nc(N)sc2C1 |
| InChI | InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m1/s1 |
| InChI Key | FASDKYOPVNHBLU-ZETCQYMHSA-N |
| MSDS | msds/12094_1_104632_26_0.pdf |
| Bioactivity | Pramipexole is a dopamine agonist of the non-ergoline class indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS).Target: Dopamine Receptor Pramipexole also possesses low/insignificant affinity (500-10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors. It has negligible affinity (>10,000 nM) for the D1, D5, 5-HT2, α1-adrenergic, β-adrenergic, H1, and mACh receptors. All sites assayed were done using human tissues. While pramipexole is used clinically, its D3-preferring receptor binding profile has made it a popular tool compound for preclinical research. Pramipexole has been used (in combination with D2- and or D3-preferring antagonists) to interrogate the role of D3 receptor function in rodent models and tasks for neuropsychiatric disorders [1-3]. Related Catalog Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease References [1]. Kvernmo, T., S. Hartter, and E. Burger, A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78. [2]. Millan, M.J., et al., Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther, 2002. 3 [3]. Weber, M., et al., Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. Behav Pharmacol, 2008. 19(8): p. 786-95. Chemical & Physical Properties Density 1.2±0.1 g/cm3 Boiling Point 378.0±42.0 °C at 760 mmHg Melting Point 288-290°C Molecular Formula C10H17N3S Molecular Weight 211.327 Flash Point 182.4±27.9 °C Exact Mass 211.114319 PSA 79.18000 LogP 1.42 Vapour Pressure 0.0±0.9 mmHg at 25°C Index of Refraction 1.583 InChIKey FASDKYOPVNHBLU-ZETCQYMHSA-N SMILES CCCNC1CCc2nc(N)sc2C1 Storage condition -20°C Freezer |
| Use of | Pramipexole is a dopamine agonist of the non-ergoline class indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS).Target: Dopamine Receptor Pramipexole also possesses low/insignificant affinity (500-10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors. It has negligible affinity (>10,000 nM) for the D1, D5, 5-HT2, α1-adrenergic, β-adrenergic, H1, and mACh receptors. All sites assayed were done using human tissues. While pramipexole is used clinically, its D3-preferring receptor binding profile has made it a popular tool compound for preclinical research. Pramipexole has been used (in combination with D2- and or D3-preferring antagonists) to interrogate the role of D3 receptor function in rodent models and tasks for neuropsychiatric disorders [1-3]. Properties Name pramipexole Synonym More Synonyms Pramipexole Biological Activity Description Pramipexole is a dopamine agonist of the non-ergoline class indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS).Target: Dopamine Receptor Pramipexole also possesses low/insignificant affinity (500-10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors. It has negligible affinity (>10,000 nM) for the D1, D5, 5-HT2, α1-adrenergic, β-adrenergic, H1, and mACh receptors. All sites assayed were done using human tissues. While pramipexole is used clinically, its D3-preferring receptor binding profile has made it a popular tool compound for preclinical research. Pramipexole has been used (in combination with D2- and or D3-preferring antagonists) to interrogate the role of D3 receptor function in rodent models and tasks for neuropsychiatric disorders [1-3]. Related Catalog Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease References [1]. Kvernmo, T., S. Hartter, and E. Burger, A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78. [2]. Millan, M.J., et al., Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther, 2002. 3 [3]. Weber, M., et al., Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. Behav Pharmacol, 2008. 19(8): p. 786-95. Chemical & Physical Properties Molecular Formula C10H17N3S Exact Mass 211.114319 PSA 79.18000 Index of Refraction 1.583 InChIKey FASDKYOPVNHBLU-ZETCQYMHSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Pioglitazone hydrochloride | 112529-15-4 | 2A-9012028 |
| Piroxicamum | 36322-90-4 | 2A-9012051 |
| Pitavastatin calcium | 147526-32-7 | 2A-9012056 |
| Poly(estradiol phosphate) | 34828-67-6 | 2A-0202304 |
| Potassium benzylpenicillin | 113-98-4 | 2A-9012085 |
| Pravastatin | 81093-37-0 | 2A-9012101 |
| Pravastatin sodium | 81131-70-6 | 2A-9012102 |
| Praziquantel | 55268-74-1 | 2A-9012104 |
| Probenecid | 57-66-9 | 2A-9012127 |
| Procaine penicillin G | 54-35-3 | 2A-9012131 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS